Founding Partners

Ab Initio Pharma is an independent limited company that was established to provide R&D and manufacturing services. Ab Initio was supported by the Federal growth Centre, MTP Connect, the University of Sydney, NSW Government Health’s Sydney Local Health District and ARCS Australia. These organisations form part of an ongoing partnership to develop a thriving pharmaceutical ecosystem in Australia.

Sydney Local Health District (SLHD)

With about 16,000 staff, Sydney Local Health District is responsible for the health and wellbeing of more than 740,000 people living within our boundaries, as well as many more from rural and remote parts of NSW and Australia. SLHD has a long and proud history of health and medical research across the healthcare continuum; with more than 60 departments involved in research from the newborn care unit at Royal Prince Alfred Hospital to research in the elderly at the Centre for Education and Research in Aging at Concord Repatriation General Hospital.

The University of Sydney

The University of Sydney is Australia’s first university.  

For over 170 years, we’ve been finding innovative solutions to the problems that matter. Our vision for the next decade is unashamedly aspirational: to be known as a place where our education is transformational, where our community thrives through diversity, and our research tackles the world’s greatest challenges.  Whether in small steps, or giant leaps, the things we do today will change tomorrow. When leadership is for all of us, it is leadership for good. 

 

ARCS Australia

ARCS is an Australian based professional organisation which focuses on career long professional development for its members in the therapeutic goods sector. ARCS provides education, competency building and information sharing within communities of practice, and targeted advocacy and collaboration with a range of stakeholders.

MTPConnect

Formed in December 2015 as part of the Federal Government’s Industry Growth Centres Initiative, MTPConnect is an independent, not-for-profit organisation. MTPConnect is forging stronger connections between research and industry to help maximise opportunities for Australians to not only make scientific and technological breakthroughs, but to see them developed through the proof-of-concept stage and successfully translated and commercialised. In this way, MTPConnect is building a more resilient and competitive medical products sector.

 
 

Awards

Australia Financial Review

Ab Initio was listed in the Australia Financial Review as one of the fastest growing start-up companies in Australia, being ranked in the 2022 AFR Fast Starters List.

Ab Initio ranked Ab Initio  26th in the  Fast Starters List, across all industry sectors ,with a 409% CAGR over the its first 2 years of operation.